NEW YORK, Jan. 7, 2022 /CNW/ -- Mind Medicine (MindMed)
Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a
leading biotech company developing psychedelic-derived therapies,
announces the resignation of Stephen
Hurst from his role as a Director of the Company's Board of
Directors.
"On behalf of MindMed, the Board of Directors, and the Executive
team, I thank Steve for his significant contributions and strategic
guidance in bringing the Company to this stage of development,"
said Robert Barrow, Chief Executive
Officer and Director of MindMed. "The co-founders and early
leadership of MindMed have been instrumental in establishing the
Company and its strong foundation. Their work, vision, and the
programs that they initiated will continue to serve as the basis
for our execution of the Company's mission. As we approach
important milestones across our clinical development programs, we
are extremely grateful for Steve's effort to enable this
progress."
Mr. Hurst added "MindMed is the culmination of my career and
more than a decade of work to bring the benefits of
psychedelic-inspired medicines to patients struggling with
addiction and mental illness. With the recent appointment of two
seasoned Directors and a brilliant Chief Executive Officer, I
have the greatest confidence in the team's ability to guide the
Company through this next phase of continued progress toward the
realization of our highest aspirations."
About MindMed
MindMed is a clinical-stage biotech company that seeks to
discover, develop and deploy psychedelic-inspired medicines and
therapies to address mental health and addiction. The Company is
assembling a compelling drug development pipeline of innovative
treatments based on psychedelic substances including psilocybin,
LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed
executive team brings extensive biopharmaceutical experience to
MindMed's approach to developing the next generation of
psychedelic-inspired medicines and therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED. MindMed is also traded in Germany under the symbol MMQ.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download
multimedia:https://www.prnewswire.com/news-releases/stephen-hurst-resigns-from-mindmed-board-of-directors-301456563.html
SOURCE Mind Medicine (MindMed) Inc.